{
    "clinical_study": {
        "@rank": "146344", 
        "arm_group": [
            {
                "arm_group_label": "PDT Standard Fluence, ranibizumab", 
                "arm_group_type": "Experimental", 
                "description": "verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab"
            }, 
            {
                "arm_group_label": "PDT Reduced Fluence, ranibizumab", 
                "arm_group_type": "Experimental", 
                "description": "verteporfin (6 mg/m2) RF ( wavelength,\t689\tnm;\tdose,\t25\tJ/cm2 ;\tlight intensity, 300 mW/cm2 for 83 s)  plus 0.5 mg intravitreal ranibizumab"
            }, 
            {
                "arm_group_label": "ranibizumab", 
                "arm_group_type": "Experimental", 
                "description": "0.5 mg (10 mg/ml)  intravitreal ranibizumab."
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate the efficacy of ranibizumab in combination with reduced-fluence verteporfin\n      photodynamic therapy (RF-PDT) in patients with subfoveal choroidal neovascularization\n      secondary to pathologic myopia (PM)."
        }, 
        "brief_title": "Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Myopia, Degenerative", 
        "condition_browse": {
            "mesh_term": [
                "Myopia", 
                "Neovascularization, Pathologic", 
                "Myopia, Degenerative", 
                "Choroidal Neovascularization"
            ]
        }, 
        "detailed_description": {
            "textblock": "Sixty patients  received ranibizumab 0.5 mg combined with reduced fluence (RF) verteporfin\n      PDT. Ranibizumab was first administered  to patients followed after seven days by RF-PDT.\n      Subsequently intravitreal ranibizumab (IVR) was injected as needed (pro re nata). All\n      patients were evaluated every 4 weeks for 48 weeks.\n\n      Main Outcome Measures: Mean change in best-corrected visual acuity (BCVA) from baseline at\n      48 weeks, reduced mean central foveal thickness (CFT) analyzed by optical coherence\n      tomography (OCT) and improved macular sensitivity registered at microperimetry (MP)\n      evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pathologic myopia, defined as spherical equivalent greater than 6 D and axial length\n             more than 26 mm (Carl Zeiss IOLMaster V 4.07; Carl Zeiss Meditec, Dublin, California,\n             USA);\n\n          -  posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy,\n             papillary crescent);\n\n          -  fluorescein angiography (FA) detection of the subfoveal or juxtafoveal CNV (CNV was\n             classified as juxta-foveal if the lesion was closer than 200 mm but not under the\n             geometric center of the foveal avascular zone);\n\n          -  clear ocular media;\n\n          -  duration of symptoms no longer than 4 weeks before enrollment.\n\n        Exclusion Criteria:\n\n          -  prior treatment for CNV including previous intravitreal drugs injection or PDT-V;\n\n          -  presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion;\n\n          -  history of recent myocardial infarction or other thromboembolic events;\n\n          -  ongoing uncontrolled hypertension or glaucoma;\n\n          -  refractive media opacities;\n\n          -  eye surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968486", 
            "org_study_id": "fidelio"
        }, 
        "intervention": [
            {
                "arm_group_label": "PDT Standard Fluence, ranibizumab", 
                "description": "In the verteporfin PDT combination therapy arm patients were treated on day one with  0.5 mg  (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 \u03bcm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.", 
                "intervention_name": "PDT standard fluence, ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Photodynamic therapy"
            }, 
            {
                "arm_group_label": "PDT Reduced Fluence, ranibizumab", 
                "description": "In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength,\t689\tnm;\tdose,\t25\tJ/cm2 ;\tlight intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 \u03bcm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.", 
                "intervention_name": "PDT reduced fluence, ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Photodynamic therapy"
            }, 
            {
                "arm_group_label": "ranibizumab", 
                "description": "In the ranibizumab monotherapy arm patients were treated with a loading phase of  three consecutive 0.5 mg  (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a  30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 \u03bcm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.", 
                "intervention_name": "ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Verteporfin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 25, 2013", 
        "number_of_arms": "3", 
        "official_title": "Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results", 
        "overall_official": {
            "affiliation": "Second University of Naples", 
            "last_name": "Flavia Chiosi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean change in best-corrected visual acuity (BCVA) from baseline", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968486"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Second University of Naples", 
            "investigator_full_name": "Chiosi Flavia", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Second University of Naples", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Second University of Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}